Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2000

View Archived Issues

Pentacea enters phase I/II trials as solid tumor therapy; receives orphan drug designation

Medicure receives second U.S. patent for cardiovascular drug

Shire updates R&D progress for year-end 1999

Cubist presents phase II data for daptomycin

KR-30035, an improved MDR modulator from the verapamil class

AGE crosslink breaker effective in nondiabetic animals with myocardial stiffness

Abbott acquires exclusive marketing rights for Actos in Latin America from Takeda

Nabi and the NIDA begin toxicity studies of Nabi-NicVAX

Dexanabinol successfully completes phase II trials

White House teams up with industry to launch the Millennium Vaccine Initiative

BTG outlicenses factor IX gene to Avigen

InKine initiates pharmacokinetic study of tablet formulation of CBP-1011

SmithKline Beecham reaffirms commitment to preventing, treating diseases in the developing world

Solid oral formulations of eprosartan with enhanced bioavailability

Antitumor/antiallergic agents discovered at Teijin

Esters providing sustained release of MDL-100907 prepared at Aventis

Taisho presents new interleukin production inhibitors with nitroaniline structure

Prostanoid receptor ligands with selectivity for EP4 receptors designed by Ono researchers

FDA grants fast track status to arsenic trioxide

Yamanouchi exercises option to license three Searle compounds

Injectable carvedilol formulations successfully developed

Yamanouchi begins rolling out Infergen in new markets

Immtech scales up production of DB-289; initiation of phase I testing later this year

Inducer of phenotypic reversion; isolation, structure and activity of new trichostatin

Dynavax's ragweed immunotherapy has improved safety according to preclinical and clinical data

The FDA approves once-daily Singulair tablet for treatment of asthma in young children

Long-term bosentan therapy attenuates progression of LV dysfunction and remodeling in heart failure